EMA – Page 9 – Pharma.Tips

Species selection questioned during program hold risk review – CAPA for study design gaps

Investigating Species Selection Questions During Program Hold Risk Reviews In the fast-evolving landscape of pharmaceutical research, one of the critical components of successful drug development is the selection of appropriate…

Study design not regulator-aligned during program hold risk review – FDA/EMA non-clinical expectations

Investigating Misalignment in Study Design During Program Hold Risk Review In the complex landscape of pharmaceutical development, study design that does not align with regulatory expectations from the FDA and…

Study design not regulator-aligned during regulatory submission prep – regulatory deficiency risk analysis

Assessing Regulatory Misalignment in Study Design During Submission Preparation In the drug development landscape, misalignments in study design during regulatory submission preparation can result in significant deficiencies, impacting timelines and…

Study design not regulator-aligned during study audit – preventing clinical hold

Addressing Non-Aligned Study Design during Regulatory Audits to Prevent Clinical Holds In the pharmaceutical industry, the alignment of study design with regulatory expectations is crucial to minimize the risk of…

GLP readiness concerns during regulatory submission prep – regulatory deficiency risk analysis

Investigating GLP Readiness Issues During Regulatory Submission Preparation During the preparation for regulatory submissions, especially for preclinical studies meant to support Investigational New Drug (IND) applications, Good Laboratory Practice (GLP)…

Species selection questioned during program hold risk review – regulatory deficiency risk analysis

Investigating Species Selection Concerns during Program Hold Risk Reviews In the dynamic landscape of pharmaceutical research and drug development, regulatory agencies such as the FDA and EMA require that preclinical…

Study design not regulator-aligned during regulatory submission prep – CAPA for study design gaps

Addressing Regulatory Misalignment in Study Design during Submission Preparation In the field of pharmaceutical manufacturing and development, ensuring compliance with regulatory expectations is paramount, especially during study design for IND…

Non-clinical toxicity findings during study audit – regulatory deficiency risk analysis

Analyzing Non-clinical Toxicity Findings in Study Audits to Mitigate Regulatory Risks In the realm of pharmaceutical drug development, ensuring the integrity and reliability of preclinical studies is paramount for advancing…

GLP readiness concerns during regulatory submission prep – FDA/EMA non-clinical expectations

Addressing GLP Readiness Issues During Regulatory Submission Preparations Good Laboratory Practice (GLP) compliance is critical in preclinical studies, as it lays the foundation for regulatory submissions to agencies such as…

Dose justification weak during sponsor oversight – CAPA for study design gaps

Weak Dose Justification During Sponsor Oversight: An Investigation into CAPA for Study Design Gaps The pharmaceutical industry often encounters challenges around effective oversight during study design, particularly regarding dose justification…

Study design not regulator-aligned during study audit – CAPA for study design gaps

Investigation of Study Design Gaps During Regulatory Audits: Aligning with Expectations During a recent study audit, your organization’s research faced scrutiny over study design elements that were found not to…

Reproducibility gaps during sponsor oversight – regulatory deficiency risk analysis

“`html Addressing Reproducibility Gaps During Sponsor Oversight to Mitigate Regulatory Deficiency Risks In the context of pharmaceutical development, reproducibility gaps in preclinical studies can lead to significant regulatory deficiencies and…